These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 21730113)

  • 1. Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.
    Duan S; Boltz DA; Li J; Oshansky CM; Marjuki H; Barman S; Webby RJ; Webster RG; Govorkova EA
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4718-27. PubMed ID: 21730113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1.
    Duwe S; Schweiger B
    J Virol Methods; 2008 Nov; 153(2):134-41. PubMed ID: 18725246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
    Takashita E; Meijer A; Lackenby A; Gubareva L; Rebelo-de-Andrade H; Besselaar T; Fry A; Gregory V; Leang SK; Huang W; Lo J; Pereyaslov D; Siqueira MM; Wang D; Mak GC; Zhang W; Daniels RS; Hurt AC; Tashiro M
    Antiviral Res; 2015 May; 117():27-38. PubMed ID: 25721488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
    Sheu TG; Deyde VM; Okomo-Adhiambo M; Garten RJ; Xu X; Bright RA; Butler EN; Wallis TR; Klimov AI; Gubareva LV
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3284-92. PubMed ID: 18625765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.
    Marjuki H; Mishin VP; Sleeman K; Okomo-Adhiambo M; Sheu TG; Guo L; Xu X; Gubareva LV
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5209-15. PubMed ID: 23917311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
    Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK
    J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
    McKimm-Breschkin JL
    Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):25-36. PubMed ID: 23279894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.
    Nakauchi M; Ujike M; Obuchi M; Takashita E; Takayama I; Ejima M; Oba K; Konomi N; Odagiri T; Tashiro M; Kageyama T;
    J Med Virol; 2011 Jul; 83(7):1121-7. PubMed ID: 21567417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
    Pizzorno A; Abed Y; Bouhy X; Beaulieu E; Mallett C; Russell R; Boivin G
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1208-14. PubMed ID: 22203589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
    Kossyvakis A; Mentis AA; Tryfinopoulou K; Pogka V; Kalliaropoulos A; Antalis E; Lytras T; Meijer A; Tsiodras S; Karakitsos P; Mentis AF
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):361-371. PubMed ID: 27848039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
    Stoner TD; Krauss S; DuBois RM; Negovetich NJ; Stallknecht DE; Senne DA; Gramer MR; Swafford S; DeLiberto T; Govorkova EA; Webster RG
    J Virol; 2010 Oct; 84(19):9800-9. PubMed ID: 20660186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y; Baz M; Boivin G
    Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis.
    Redlberger-Fritz M; Aberle SW; Strassl R; Popow-Kraupp T
    Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1593-601. PubMed ID: 22089329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.
    Kwon JJ; Choi WS; Jeong JH; Kim EH; Lee OJ; Yoon SW; Hwang J; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
    J Gen Virol; 2018 Mar; 99(3):292-302. PubMed ID: 29493493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors.
    Adams SE; Lee N; Lugovtsev VY; Kan A; Donnelly RP; Ilyushina NA
    Antiviral Res; 2019 Sep; 169():104539. PubMed ID: 31228489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
    Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
    Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.
    Takashita E; Fujisaki S; Kishida N; Xu H; Imai M; Tashiro M; Odagiri T;
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1390-9. PubMed ID: 23745712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.
    LeGoff J; Rousset D; Abou-Jaoudé G; Scemla A; Ribaud P; Mercier-Delarue S; Caro V; Enouf V; Simon F; Molina JM; van der Werf S
    PLoS One; 2012; 7(8):e37095. PubMed ID: 22936969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.